Awada, G.; Jansen, Y.; Schwarze, J.K.; Tijtgat, J.; Hellinckx, L.; Gondry, O.; Vermeulen, S.; Warren, S.; Schats, K.; van Dam, P.-J.;
et al. A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers 2021, 13, 168.
https://doi.org/10.3390/cancers13020168
AMA Style
Awada G, Jansen Y, Schwarze JK, Tijtgat J, Hellinckx L, Gondry O, Vermeulen S, Warren S, Schats K, van Dam P-J,
et al. A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers. 2021; 13(2):168.
https://doi.org/10.3390/cancers13020168
Chicago/Turabian Style
Awada, Gil, Yanina Jansen, Julia Katharina Schwarze, Jens Tijtgat, Lennert Hellinckx, Odrade Gondry, Sim Vermeulen, Sarah Warren, Kelly Schats, Pieter-Jan van Dam,
and et al. 2021. "A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab" Cancers 13, no. 2: 168.
https://doi.org/10.3390/cancers13020168
APA Style
Awada, G., Jansen, Y., Schwarze, J. K., Tijtgat, J., Hellinckx, L., Gondry, O., Vermeulen, S., Warren, S., Schats, K., van Dam, P. -J., Kockx, M., Keyaerts, M., Everaert, H., Seremet, T., Rogiers, A., & Neyns, B.
(2021). A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers, 13(2), 168.
https://doi.org/10.3390/cancers13020168
